Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) Director Joshua S. Boger sold 5,200 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $93.31, for a total transaction of $485,212.00. Following the completion of the transaction, the director now directly owns 338,895 shares in the company, valued at approximately $31,622,292. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on VRTX shares. Analysts at Zacks reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, July 31st. They now have a $97.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 9th. Finally, analysts at Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $102.82.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 0.25% during mid-day trading on Thursday, hitting $92.80. 558,165 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 52-week low of $58.06 and a 52-week high of $99.74. The stock’s 50-day moving average is $92.43 and its 200-day moving average is $79.30. The company’s market cap is $22.094 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Tuesday, July 29th. The company reported ($0.61) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.71) by $0.10. The company had revenue of $138.42 million for the quarter, compared to the consensus estimate of $131.85 million. During the same quarter last year, the company posted ($0.03) earnings per share. Vertex Pharmaceuticals’s revenue was down 55.5% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals will post $-2.90 EPS for the current fiscal year.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.